Scientists in Australia have studied how lung cancer cell metabolism influences patient responses to immunotherapy. Researchers from the University of Queensland’s Frazer Institute focused on non-small cell lung carcinoma to understand why some patients do not benefit from immunotherapy. By analyzing cell interactions and glucose metabolism using advanced algorithms, they identified metabolic neighborhoods linked to treatment response and resistance. This research is crucial as immunotherapy is expensive and effective for only a small patient group.
Lead author James Monkman highlighted that increased glucose uptake in cancer cells is associated with poorer outcomes. The team observed variations in glucose processing within different regions of tumors, indicating diverse metabolic activities. The study, published in Nature Communications, aims to pave the way for targeted treatments like metabolic inhibitors to enhance the efficacy of immunotherapy. The researchers plan to extend this approach to other cancer types for personalized precision medicine.
